FI120357B - Menetelmiä ja koostumuksia heterologisten polypeptidien erittämiseksi - Google Patents

Menetelmiä ja koostumuksia heterologisten polypeptidien erittämiseksi Download PDF

Info

Publication number
FI120357B
FI120357B FI973559A FI973559A FI120357B FI 120357 B FI120357 B FI 120357B FI 973559 A FI973559 A FI 973559A FI 973559 A FI973559 A FI 973559A FI 120357 B FI120357 B FI 120357B
Authority
FI
Finland
Prior art keywords
seq
atg
ttt
ctt
tct
Prior art date
Application number
FI973559A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI973559A (fi
FI973559A0 (fi
Inventor
Daniel G Yansura
Laura C Simmons
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of FI973559A0 publication Critical patent/FI973559A0/fi
Publication of FI973559A publication Critical patent/FI973559A/fi
Application granted granted Critical
Publication of FI120357B publication Critical patent/FI120357B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)
  • External Artificial Organs (AREA)
FI973559A 1995-03-01 1997-08-29 Menetelmiä ja koostumuksia heterologisten polypeptidien erittämiseksi FI120357B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39861595 1995-03-01
US08/398,615 US5840523A (en) 1995-03-01 1995-03-01 Methods and compositions for secretion of heterologous polypeptides
US9602858 1996-02-27
PCT/US1996/002858 WO1996027016A1 (en) 1995-03-01 1996-02-27 Methods and compositions for secretion of heterologous polypeptides

Publications (3)

Publication Number Publication Date
FI973559A0 FI973559A0 (fi) 1997-08-29
FI973559A FI973559A (fi) 1997-10-29
FI120357B true FI120357B (fi) 2009-09-30

Family

ID=23576066

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973559A FI120357B (fi) 1995-03-01 1997-08-29 Menetelmiä ja koostumuksia heterologisten polypeptidien erittämiseksi

Country Status (18)

Country Link
US (1) US5840523A (no)
EP (1) EP0815246B1 (no)
JP (1) JP3375970B2 (no)
CN (1) CN1154736C (no)
AT (1) ATE358181T1 (no)
AU (1) AU701476B2 (no)
BR (1) BR9607464B1 (no)
CA (1) CA2213813C (no)
DE (1) DE69636996T2 (no)
DK (1) DK0815246T3 (no)
ES (1) ES2285711T3 (no)
FI (1) FI120357B (no)
IL (1) IL117314A0 (no)
NO (1) NO324920B1 (no)
NZ (1) NZ303619A (no)
RU (1) RU2208639C2 (no)
WO (1) WO1996027016A1 (no)
ZA (1) ZA961688B (no)

Families Citing this family (757)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242177B1 (en) * 1995-03-01 2001-06-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6824780B1 (en) * 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
EP1290197B1 (en) 2000-06-05 2006-03-29 Corixa Corporation Leader peptides for enhancing secretion of recombinant protein from a host cell
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
CA2430182C (en) * 2000-12-14 2011-01-25 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
EP2000482A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2454731C (en) * 2001-08-27 2010-11-02 Genentech, Inc. A system for antibody expression and assembly
NZ531674A (en) 2001-09-18 2009-03-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
KR100623128B1 (ko) 2002-01-02 2006-09-14 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR20050004914A (ko) * 2002-06-07 2005-01-12 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
EP1578447A4 (en) 2002-10-31 2009-06-03 Genentech Inc METHODS AND COMPOSITIONS THAT CAN INCREASE ANTIBODY PRODUCTION
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
US7575893B2 (en) * 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
JP4884224B2 (ja) 2003-05-09 2012-02-29 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
CA2534055A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
WO2005027966A2 (en) * 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
EP1689432B1 (en) 2003-11-17 2009-12-30 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
AU2004309347B2 (en) * 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
AU2005244751A1 (en) * 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting B cell depletion
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
RU2398777C2 (ru) * 2004-08-05 2010-09-10 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met
US7662926B2 (en) * 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) * 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
EP1786836A2 (en) * 2004-09-02 2007-05-23 Genentech, Inc. Anti-fc-gamma riib receptor antibody and uses therefor
MX2007002856A (es) * 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
RU2453558C2 (ru) 2004-09-03 2012-06-20 Дженентек, Инк. Гуманизированные антагонистические антитела против бета7 и их применение
NZ556635A (en) 2004-12-22 2010-11-26 Genentech Inc Method for producing soluble multi-membrane-spanning proteins
EP1841793B1 (en) 2005-01-07 2010-03-31 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
US20070161089A1 (en) * 2005-11-08 2007-07-12 Genentech, Inc. Method of Producing Pan-Specific Antibodies
NZ621483A (en) 2005-12-02 2015-10-30 Genentech Inc Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
ES2388932T3 (es) * 2005-12-02 2012-10-19 Genentech, Inc. Polipéptidos de unión y usos de los mismos
EP2325208B1 (en) 2005-12-15 2017-09-20 Genentech, Inc. Polyubiquitin antibodies
EP2330202A3 (en) 2006-01-06 2011-09-14 University Of Georgia Research Foundation, Inc. Cyst nematode resistant transgenic plants
EP2007428A2 (en) 2006-04-05 2008-12-31 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
WO2007140371A2 (en) 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
RU2486201C2 (ru) 2006-10-12 2013-06-27 Дженентек, Инк. Антитела к лимфотоксину-альфа
RU2639543C9 (ru) 2006-10-27 2018-06-14 Дженентек, Инк. Антитела и иммуноконъюгаты и их применения
WO2008067283A2 (en) 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use
AR065271A1 (es) 2007-02-09 2009-05-27 Genentech Inc Anticuerpos anti-robo4 y sus usos
CA2676790A1 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
ES2579323T3 (es) 2007-07-16 2016-08-09 Genentech, Inc. Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso
AU2008276128B2 (en) 2007-07-16 2013-10-10 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
AU2008323770B2 (en) 2007-11-07 2014-08-07 Genentech, Inc. Compositions and methods for treatment of microbial disorders
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
MX2010005244A (es) * 2007-11-12 2010-10-25 Theraclone Sciences Inc Composiciones y métodos para la terapia y el diagnóstico de influenza.
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
JP5715420B2 (ja) 2007-12-28 2015-05-07 ジェネンテック， インコーポレイテッド 抗ヘッジホッグ抗体
KR100958095B1 (ko) * 2007-12-31 2010-05-14 한국과학기술원 번역 동반 시스템을 이용한 항균 펩타이드의 대량 발현방법
CL2009000062A1 (es) 2008-01-31 2010-05-14 Genentech Inc Anticuerpo humanizado anti cd79b; con modificaciones de cisterna libre; inmunoconjugado que contiene dicho anticuerpo y una droga; polinucleotido que codifica el anticuerpo; vector, celula huesped; composicion farmaceutica y uso de dicha composicion para tratar cancer, preferentemente linfomas.
TW200942552A (en) * 2008-03-06 2009-10-16 Genentech Inc Combination therapy with c-Met and HER antagonists
CA2718878A1 (en) * 2008-03-10 2009-09-17 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
MX2011006516A (es) 2008-12-17 2011-08-04 Genentech Inc Terapia de combinacion de virus de hepatitis c.
WO2010078376A2 (en) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
RU2504553C2 (ru) 2009-03-20 2014-01-20 Дженентек, Инк. Антитела к her
PE20120878A1 (es) 2009-04-01 2012-08-06 Genentech Inc ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
PL2417156T3 (pl) 2009-04-07 2015-07-31 Roche Glycart Ag Trójwartościowe, bispecyficzne przeciwciała
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
CN102459340A (zh) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
US8858948B2 (en) 2009-05-20 2014-10-14 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
KR20120051733A (ko) 2009-08-04 2012-05-22 에프. 호프만-라 로슈 아게 베타 세포 마커 항체
ES2599076T3 (es) 2009-09-02 2017-01-31 Genentech, Inc. Smoothened mutante y métodos de utilización del mismo
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US20110206704A1 (en) * 2009-10-19 2011-08-25 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activator
US8759491B2 (en) * 2009-10-19 2014-06-24 Genentech, Inc. Modulators of hepatocyte growth factor activator
BR112012009409A2 (pt) 2009-10-22 2017-02-21 Genentech Inc método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
SI2496601T1 (sl) * 2009-11-05 2017-09-29 F. Hoffmann-La Roche Ag Tehnike in sestavek za sekrecijo heterolognih polipeptidov
BR112012012213A2 (pt) 2009-11-26 2017-01-10 Hoffmann La Roche proteína marcada para diabetes do tipo 2
TWI507524B (zh) 2009-11-30 2015-11-11 Genentech Inc 診斷及治療腫瘤之組合物及方法
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
TWI505836B (zh) 2009-12-11 2015-11-01 Genentech Inc 抗－ｖｅｇｆ－ｃ抗體及其使用方法
EP3616719A1 (en) 2009-12-21 2020-03-04 F. Hoffmann-La Roche AG Antibody formulation
SI2536748T1 (sl) 2010-02-18 2014-12-31 Genentech, Inc. Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR101899835B1 (ko) 2010-03-24 2018-09-19 제넨테크, 인크. 항-ｌｒｐ６ 항체
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
WO2011143262A2 (en) 2010-05-10 2011-11-17 Sinica, Academia Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
HRP20171095T4 (hr) 2010-05-25 2022-07-22 F. Hoffmann - La Roche Ag Postupci pročišćavanja polipeptida
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2577310B1 (en) 2010-06-03 2018-11-14 F.Hoffmann-La Roche Ag Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
TW201204388A (en) 2010-06-18 2012-02-01 Genentech Inc Anti-Axl antibodies and methods of use
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
CN103097418A (zh) 2010-07-09 2013-05-08 霍夫曼-拉罗奇有限公司 抗神经毡蛋白抗体及使用方法
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
WO2012017003A1 (en) 2010-08-05 2012-02-09 F. Hoffmann-La Roche Ag Anti-mhc antibody anti-viral cytokine fusion protein
EP2603237A4 (en) 2010-08-12 2014-05-21 Theraclone Sciences Inc ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
KR20130100125A (ko) 2010-08-13 2013-09-09 제넨테크, 인크. 질환의 치료를 위한, ＩＬ-1β 및 ＩＬ-18에 대한 항체
CN103168049B (zh) 2010-08-13 2015-10-07 罗切格利卡特公司 抗生腱蛋白-c a2抗体及使用方法
PT2603530T (pt) 2010-08-13 2018-01-09 Roche Glycart Ag Anticorpos anti-fap e métodos de utilização
MX340558B (es) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
WO2012025536A1 (en) 2010-08-25 2012-03-01 F. Hoffmann-La Roche Ag Antibodies against il-18r1 and uses thereof
CA3059961C (en) 2010-08-31 2021-04-13 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
ES2588981T3 (es) 2010-10-05 2016-11-08 Genentech, Inc. Smoothened mutante y métodos de uso de la misma
ES2607086T3 (es) 2010-11-10 2017-03-29 F. Hoffmann-La Roche Ag Métodos y composiciones para la inmunoterapia de enfermedades neuronales
CA2817380C (en) 2010-12-16 2019-06-04 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
TWI589589B (zh) 2010-12-20 2017-07-01 建南德克公司 抗間皮素（ｍｅｓｏｔｈｅｌｉｎ）抗體及免疫接合物
KR20130118925A (ko) 2010-12-22 2013-10-30 제넨테크, 인크. 항-pcsk9 항체 및 사용 방법
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
JP2014502607A (ja) 2011-01-03 2014-02-03 エフ．ホフマン−ラ ロシュ アーゲー 抗ｄｉｇ抗体およびペプチドと結合体化しているジゴキシゲニンの複合体の薬学的組成物
EP2675478A4 (en) 2011-02-14 2015-06-10 Theraclone Sciences Inc COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF GRIP
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
KR101638224B1 (ko) 2011-02-28 2016-07-08 에프. 호프만-라 로슈 아게 항원 결합 단백질
EP2685968A1 (en) 2011-03-15 2014-01-22 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
CN103596983B (zh) 2011-04-07 2016-10-26 霍夫曼-拉罗奇有限公司 抗fgfr4抗体及使用方法
BR112013026423A2 (pt) 2011-04-20 2016-11-29 Roche Glycart Ag método e construtos para a passagem de pendente do ph da barreira sangue-cérebro
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
PT2710035T (pt) 2011-05-16 2017-06-05 Hoffmann La Roche Agonistas do fgfr1 e métodos de utilização
RU2013158594A (ru) 2011-06-15 2015-07-20 Ф. Хоффманн-Ля Рош Аг Антитело, связывающееся с полипептидом авса1
US8623666B2 (en) 2011-06-15 2014-01-07 Hoffmann-La Roche Inc. Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies
PE20141212A1 (es) 2011-06-22 2014-09-19 Hoffmann La Roche Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase 1
KR20140045440A (ko) 2011-06-30 2014-04-16 제넨테크, 인크. 항-c-met 항체 제제
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
KR20140057326A (ko) 2011-08-17 2014-05-12 제넨테크, 인크. 뉴레귤린 항체 및 그의 용도
CA2844141A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Anti-mcsp antibodies
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
CA2846083A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation
MX2014002996A (es) 2011-09-23 2014-05-28 Roche Glycart Ag Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
BR112014008212A2 (pt) 2011-10-05 2017-06-13 Genentech Inc método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar
TW201321414A (zh) 2011-10-14 2013-06-01 Genentech Inc 抗－ＨｔｒＡ１抗體及其使用方法
CA2850836A1 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
EP2771363A1 (en) 2011-10-26 2014-09-03 The Regents of The University of California Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies
MX2014004991A (es) 2011-10-28 2014-05-22 Genentech Inc Combinaciones terapeuticas y metodos para tratar el melanoma.
FI3091029T3 (fi) 2011-10-31 2023-03-20 Hoffmann La Roche Anti-il13-vasta-aineformulaatioita
TW201326193A (zh) 2011-11-21 2013-07-01 Genentech Inc 抗－ｃ－ｍｅｔ抗體之純化
US20130143237A1 (en) 2011-11-29 2013-06-06 Genentech, Inc. Compositions and methods for prostate cancer analysis
CN110078831A (zh) 2011-12-01 2019-08-02 圆祥生命科技股份有限公司 补体和vegf途径的蛋白质抑制剂及其使用方法
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
CN113896787A (zh) 2011-12-22 2022-01-07 弗·哈夫曼-拉罗切有限公司 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
JP2015503907A (ja) 2011-12-22 2015-02-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 真核細胞のための全長抗体提示システムおよびその使用
EP3816284A1 (en) 2011-12-22 2021-05-05 F. Hoffmann-La Roche AG Expression vector for antibody production in eukaryotic cells
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
CA2862979A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
CN104168920A (zh) 2012-01-18 2014-11-26 霍夫曼-拉罗奇有限公司 使用fgf19调控剂的方法
SG11201404198TA (en) 2012-01-18 2014-08-28 Genentech Inc Anti-lrp5 antibodies and methods of use
BR112014018471A2 (pt) 2012-01-31 2017-07-04 Genentech Inc anticorpos anti-ige m1' e métodos para o seu uso
KR20140127854A (ko) 2012-02-10 2014-11-04 제넨테크, 인크. 단일-쇄 항체 및 다른 이종다량체
AU2013216753B2 (en) 2012-02-11 2017-09-21 Genentech, Inc. R-spondin translocations and methods using the same
ES2676031T3 (es) 2012-02-15 2018-07-16 F. Hoffmann-La Roche Ag Cromatografía de afinidad basada en el receptor Fc
RU2014140137A (ru) 2012-03-08 2016-04-27 Ф.Хоффманн-Ля Рош Аг Лекарственный препарат антитела к бета-амилоиду
BR112014024017A8 (pt) 2012-03-27 2017-07-25 Genentech Inc Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
RU2014143251A (ru) 2012-03-28 2016-05-20 Дженентек, Инк. Антиидиотипические антитела к hcmv и их применение
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
CA2865676C (en) 2012-04-17 2020-03-10 Stefan Klostermann Method for the expression of polypeptides using modified nucleic acids
AU2013256596A1 (en) 2012-05-01 2014-10-09 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
CA2870876C (en) 2012-05-23 2019-10-01 Genentech, Inc. Selection method for therapeutic agents
MX2014014830A (es) 2012-06-15 2015-05-11 Genentech Inc Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso.
EP2863954A1 (en) 2012-06-21 2015-04-29 Indiana University Research and Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
CN104395340B9 (zh) 2012-06-27 2018-11-30 弗·哈夫曼-拉罗切有限公司 包含至少两个不同靶向实体的定制选择性和多特异性治疗分子的方法及其用途
WO2014006124A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
MX353951B (es) 2012-07-04 2018-02-07 Hoffmann La Roche Anticuerpos de anti-teofilina y metodos de uso.
EP3339328A1 (en) 2012-07-04 2018-06-27 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
CN110042114B (zh) 2012-07-05 2024-09-10 弗·哈夫曼-拉罗切有限公司 表达和分泌系统
AU2013288932A1 (en) 2012-07-09 2014-12-11 Genentech, Inc. Immunoconjugates comprising anti - CD79b antibodies
SG11201500087VA (en) 2012-07-09 2015-02-27 Genentech Inc Immunoconjugates comprising anti-cd22 antibodies
MX2015000315A (es) 2012-07-09 2015-07-06 Genentech Inc Anticuerpos anti-cd22 e inmunoconjugados.
JP2015523380A (ja) 2012-07-09 2015-08-13 ジェネンテック， インコーポレイテッド 抗ｃｄ７９ｂ抗体を含む免疫複合体
PE20150361A1 (es) 2012-07-13 2015-03-14 Roche Glycart Ag Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
KR20150038511A (ko) 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 불활성 면역글로불린 Ｆｃ-영역을 갖는 Ｆｃ-융합체로서의 가용성 ＦｃＲ 의 생산 방법 및 그의 용도
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2014031762A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
EP2895496B1 (en) 2012-09-14 2017-06-07 F. Hoffmann-La Roche AG Method for the production and selection of molecules comprising at least two different entities and uses thereof
US20140081003A1 (en) 2012-09-19 2014-03-20 Genentech, Inc. Methods and compositions for preventing norleucine misincorporation into proteins
CA2884431A1 (en) 2012-11-08 2014-05-15 F. Hoffmann-La Roche Ag Her3 antigen binding proteins binding to the beta-hairpin of her3
CN104968367B (zh) 2012-11-13 2018-04-13 弗·哈夫曼-拉罗切有限公司 抗血凝素抗体和使用方法
SG11201504414UA (en) 2012-12-21 2015-07-30 Hoffmann La Roche Disulfide-linked multivalent mhc class i comprising multi-function proteins
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
EP2961772A1 (en) 2013-02-26 2016-01-06 Roche Glycart AG Anti-mcsp antibodies
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
AU2014243783B2 (en) 2013-03-13 2018-12-13 Genentech, Inc. Antibody formulations
JP6389236B2 (ja) 2013-03-13 2018-09-12 ジェネンテック， インコーポレイテッド 酸化還元製剤
BR112015022475A8 (pt) 2013-03-13 2019-11-26 Genentech Inc formulação líquida e método para impedir a oxidação de uma proteína em uma formulação de proteína
WO2014152358A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
JP6436965B2 (ja) 2013-03-14 2018-12-12 ジェネンテック， インコーポレイテッド 抗ｂ７−ｈ４抗体及びイムノコンジュゲート
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
DK2970422T3 (en) 2013-03-15 2018-07-16 Hoffmann La Roche IL-22 POLYPEPTIDES AND IL-22 FC-FUSION PROTEINS AND METHODS OF USE
JP2016513478A (ja) 2013-03-15 2016-05-16 ジェネンテック， インコーポレイテッド 細胞培養培地及び抗体を産生する方法
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
SG10201912621TA (en) 2013-03-15 2020-02-27 Genentech Inc Cell culture compositions with antioxidants and methods for polypeptide production
US9598485B2 (en) 2013-03-15 2017-03-21 Ac Immune S.A. Anti-tau antibodies and methods of use
SG10201706210WA (en) 2013-03-15 2017-09-28 Genentech Inc Compositions and methods for diagnosis and treatment of hepatic cancers
EP2970471A2 (en) 2013-03-15 2016-01-20 F. Hoffmann-La Roche AG Anti-crth2 antibodies and their use
EP2983710B1 (en) 2013-04-09 2019-07-31 Annexon, Inc. Methods of treatment for neuromyelitis optica
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
AU2014261631B2 (en) 2013-04-29 2019-02-14 F. Hoffmann-La Roche Ag FcRn-binding abolished anti-IGF-1R antibodies and their use in the treatment of vascular eye diseases
JP6618893B2 (ja) 2013-04-29 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体結合が変更された非対称抗体および使用方法
PE20151926A1 (es) 2013-05-20 2016-01-07 Genentech Inc Anticuerpos de receptores de antitransferrina y metodos de uso
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
JP6462680B2 (ja) 2013-07-09 2019-01-30 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ抗体及びその使用
SI3019516T1 (sl) 2013-07-12 2019-02-28 F. Hoffmann-La Roche Ag Določitev optimalnih vhodnih parametrov za ionsko izmenjevalno kromatografijo
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
EP2832854A1 (en) 2013-08-02 2015-02-04 F. Hoffmann-La Roche AG Method for improving the recombinant expression of a polypeptide by C-terminal fusion to human neprilysin
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
CN105682666B (zh) 2013-09-06 2021-06-01 中央研究院 使用醣脂激活人类iNKT细胞
CN105764921B (zh) 2013-09-17 2020-06-30 台湾浩鼎生技股份有限公司 用于诱导免疫反应的糖疫苗组合物及其治疗癌症的用途
CN105518027A (zh) 2013-09-17 2016-04-20 豪夫迈·罗氏有限公司 使用抗lgr5抗体的方法
EP3049437A1 (en) 2013-09-27 2016-08-03 F. Hoffmann-La Roche AG Thermus thermophilus slyd fkbp domain specific antibodies
EA201991715A1 (ru) 2013-09-27 2020-03-31 Дженентек, Инк. Композиции, содержащие антитело к pdl1
CN105814078A (zh) 2013-10-11 2016-07-27 豪夫迈·罗氏有限公司 Nsp4抑制剂及其使用方法
JP6422956B2 (ja) 2013-10-11 2018-11-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性ドメイン交換共通可変軽鎖抗体
CN105744954B (zh) 2013-10-18 2021-03-05 豪夫迈·罗氏有限公司 抗rspo2和/或抗rspo3抗体及其用途
KR20160068802A (ko) 2013-10-23 2016-06-15 제넨테크, 인크. 호산구성 장애를 진단 및 치료하는 방법
WO2015073721A1 (en) 2013-11-13 2015-05-21 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
EP3071597B1 (en) 2013-11-21 2020-07-29 F.Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
RU2737882C2 (ru) 2013-11-27 2020-12-04 Займворкс Инк. Биспецифические антигенсвязывающие конструкции против her2
EP3611191A1 (en) 2013-12-09 2020-02-19 Allakos Inc. Anti-siglec-8 antibodies and methods of use thereof
PE20160712A1 (es) 2013-12-13 2016-07-26 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33
KR20160092024A (ko) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
CN106102774A (zh) 2013-12-17 2016-11-09 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
KR20160089531A (ko) 2013-12-17 2016-07-27 제넨테크, 인크. Pd-1 축 결합 길항제 및 항-her2 항체를 사용하여 her2-양성 암을 치료하는 방법
RU2016128726A (ru) 2013-12-17 2018-01-23 Дженентек, Инк. Способы лечения злокачественных опухолей с использованием антагонистов связывания по оси pd-1 и антитела против cd20
JP2017504598A (ja) 2013-12-20 2017-02-09 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化インクレチン受容体リガンドヒト免疫グロブリンｆｃ−領域融合ポリペプチド
BR112016013562A2 (pt) 2013-12-20 2017-10-03 Hoffmann La Roche Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
CA2933384A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
CA2930154A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
EP3851452A1 (en) 2014-01-06 2021-07-21 F. Hoffmann-La Roche AG Monovalent blood brain barrier shuttle modules
CN105899534B (zh) 2014-01-15 2020-01-07 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2935393A1 (en) 2014-01-24 2015-07-30 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
SG10201901076WA (en) 2014-02-08 2019-03-28 Genentech Inc Methods of treating alzheimer's disease
TWI705824B (zh) 2014-02-08 2020-10-01 美商建南德克公司 治療阿茲海默症之方法
EP3825332A1 (en) 2014-02-12 2021-05-26 F. Hoffmann-La Roche AG Anti-jagged1 antibodies and methods of use
KR20160124165A (ko) 2014-02-21 2016-10-26 제넨테크, 인크. 항-il-13/il-17 이중특이적 항체 및 그의 용도
AU2015222757B2 (en) 2014-02-28 2020-10-08 Allakos Inc. Methods and compositions for treating Siglec-8 associated diseases
JP6644717B2 (ja) 2014-03-14 2020-02-12 ジェネンテック， インコーポレイテッド 異種ポリペプチドを分泌させるための方法及び組成物
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
EP3126386A1 (en) 2014-03-31 2017-02-08 F. Hoffmann-La Roche AG Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
PE20161571A1 (es) 2014-03-31 2017-02-07 Genentech Inc Anticuerpos anti-ox40 y metodos de uso
JP6666262B2 (ja) 2014-04-02 2020-03-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体の軽鎖誤対合を検出するための方法
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
CN106414499A (zh) 2014-05-22 2017-02-15 基因泰克公司 抗gpc3抗体和免疫偶联物
WO2015179835A2 (en) 2014-05-23 2015-11-26 Genentech, Inc. Mit biomarkers and methods using the same
KR102576850B1 (ko) 2014-05-27 2023-09-11 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
MX2016016233A (es) 2014-06-11 2017-03-31 Genentech Inc Anticuerpos anti-lgr5 y sus usos.
BR112016029935A2 (pt) 2014-06-26 2017-10-31 Hoffmann La Roche ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
SG11201700207WA (en) 2014-07-11 2017-02-27 Genentech Inc Anti-pd-l1 antibodies and diagnostic uses thereof
JP2017526641A (ja) 2014-07-11 2017-09-14 ジェネンテック， インコーポレイテッド Ｎｏｔｃｈ経路阻害
CN107106679B (zh) 2014-08-08 2022-07-26 艾利妥 抗trem2抗体及其使用方法
JP6899321B2 (ja) 2014-09-08 2021-07-07 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 糖脂質を使用するヒトｉＮＫＴ細胞活性化
EP3191518B1 (en) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
AR101846A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
PT3191135T (pt) 2014-09-12 2020-11-12 Genentech Inc Anticorpos anti-her2 e imunoconjugados
WO2016044334A1 (en) 2014-09-15 2016-03-24 Genentech, Inc. Antibody formulations
JP6730261B2 (ja) 2014-09-17 2020-07-29 ジェネンテック， インコーポレイテッド 抗ｈｅｒ２抗体を含む免疫複合体
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
CN107074938A (zh) 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
MX2017005751A (es) 2014-11-03 2018-04-10 Genentech Inc Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
SG11201703448QA (en) 2014-11-03 2017-05-30 Genentech Inc Assays for detecting t cell immune subsets and methods of use thereof
AU2015342961B2 (en) 2014-11-05 2021-08-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
CN107207587B (zh) 2014-11-05 2022-04-19 安尼艾克松股份有限公司 人源化抗-补体因子c1q抗体及其应用
ES2819256T3 (es) 2014-11-05 2021-04-15 Genentech Inc Métodos para producir proteínas bicatenarias en bacterias
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
KR20170076697A (ko) 2014-11-06 2017-07-04 에프. 호프만-라 로슈 아게 개질된 FCRN-결합 특성 및 단백질 A-결합 특성을 가진 Fc-영역 변이체
ES2749383T3 (es) 2014-11-06 2020-03-20 Hoffmann La Roche Variantes de la región Fc con unión al FcRn modificada y procedimientos de uso
EP3217787B1 (en) 2014-11-10 2019-04-17 F.Hoffmann-La Roche Ag Animal model for nephropathy and agents for treating the same
EA201791029A1 (ru) 2014-11-10 2017-12-29 Дженентек, Инк. Антитела против интерлейкина-33 и их применение
BR112017010198A2 (pt) 2014-11-17 2017-12-26 Genentech Inc terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
EP3221362B1 (en) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
EP3221364B1 (en) 2014-11-19 2020-12-16 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
CA2968258A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
AR102918A1 (es) 2014-12-05 2017-04-05 Genentech Inc Anticuerpos anti-cd79b y métodos de uso
MX2017007491A (es) 2014-12-10 2018-05-04 Genentech Inc Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
JP6618539B2 (ja) 2014-12-17 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ソルターゼを使用した酵素媒介性のポリペプチドコンジュゲーションのための方法
JP2018503368A (ja) 2014-12-18 2018-02-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｄｃを誘発する抗体を決定するためのアッセイ法および方法
MY183415A (en) 2014-12-19 2021-02-18 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
WO2016117346A1 (en) 2015-01-22 2016-07-28 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
KR102630294B1 (ko) 2015-01-24 2024-01-26 아카데미아 시니카 암 마커 및 이를 사용하는 방법
TWI736523B (zh) 2015-01-24 2021-08-21 中央研究院 新穎聚醣結合物及其使用方法
KR102620346B1 (ko) 2015-01-30 2024-01-02 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
JP2018512597A (ja) 2015-02-04 2018-05-17 ジェネンテック， インコーポレイテッド 突然変異体スムースンド及びその使用方法
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
MX2017011486A (es) 2015-03-16 2018-06-15 Genentech Inc Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
WO2016164637A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
JP2018512892A (ja) 2015-04-17 2018-05-24 エルサリー バイオテックＥｌｓａｌｙｓｂｉｏｔｅｃｈ 抗ｔｙｒｏ３抗体及びその使用
EP3286565A1 (en) 2015-04-21 2018-02-28 Genentech, Inc. Compositions and methods for prostate cancer analysis
EP3913052A1 (en) 2015-04-24 2021-11-24 F. Hoffmann-La Roche AG Methods of identifying bacteria comprising binding polypeptides
JP2018520642A (ja) 2015-05-01 2018-08-02 ジェネンテック， インコーポレイテッド マスク抗ｃｄ３抗体及びその使用方法
EP3936524A3 (en) 2015-05-11 2022-06-15 F. Hoffmann-La Roche AG Compositions and methods of treating lupus nephritis
EP3795679A1 (en) 2015-05-28 2021-03-24 Genentech, Inc. Cell-based assay for detecting anti-cd3 homodimers
CN107771182A (zh) 2015-05-29 2018-03-06 豪夫迈·罗氏有限公司 人源化抗埃博拉病毒糖蛋白抗体和使用方法
WO2016196381A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Pd-l1 promoter methylation in cancer
EP3302552A1 (en) 2015-06-02 2018-04-11 H. Hoffnabb-La Roche Ag Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
RU2732122C2 (ru) 2015-06-05 2020-09-11 Дженентек, Инк. Антитела против тау-белка и способы их применения
MX2017015937A (es) 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
MX2017014740A (es) 2015-06-08 2018-08-15 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
US11136390B2 (en) 2015-06-12 2021-10-05 Alector Llc Anti-CD33 antibodies and methods of use thereof
US10017577B2 (en) 2015-06-15 2018-07-10 Genentech, Inc. Antibodies and immunoconjugates
AR105026A1 (es) 2015-06-16 2017-08-30 Genentech Inc ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
KR20180012859A (ko) 2015-06-17 2018-02-06 제넨테크, 인크. 항-her2 항체 및 이용 방법
CA2986263A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
US10774145B2 (en) 2015-06-17 2020-09-15 Allakos Inc. Methods and compositions for treating fibrotic diseases
US9862763B2 (en) 2015-06-24 2018-01-09 Hoffmann-La Roche Inc. Humanized anti-tau(pS422) antibodies and methods of use
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
JP2018520153A (ja) 2015-06-29 2018-07-26 ジェネンテック， インコーポレイテッド 臓器移植における使用のためのｉｉ型抗ｃｄ２０抗体
AU2016288461B2 (en) 2015-06-29 2021-10-07 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
LT3124976T (lt) 2015-07-28 2018-12-27 F. Hoffmann-La Roche Ag Patobulintas bakterinio endotoksino testas, skirtas endotoksinų aptikimui
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP7525980B2 (ja) 2015-08-28 2024-07-31 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
JP6914919B2 (ja) 2015-08-28 2021-08-04 ジェネンテック， インコーポレイテッド 抗ヒプシン抗体及びその使用
EP3344806A4 (en) 2015-09-04 2019-03-20 OBI Pharma, Inc. GLYCAN NETWORKS AND METHODS OF USE
PE20181336A1 (es) 2015-09-18 2018-08-21 Chugai Pharmaceutical Co Ltd Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
AU2016328357B2 (en) 2015-09-22 2023-03-02 Ventana Medical Systems, Inc. Anti-OX40 antibodies and diagnostic uses thereof
JP6959912B2 (ja) 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
MX2018003533A (es) 2015-09-24 2019-04-25 Abvitro Llc Composiciones de anticuerpo de virus de inmunodeficiencia humana (vih) y metodos de uso.
EP3353314A1 (en) 2015-09-25 2018-08-01 H. Hoffnabb-La Roche Ag Transamidation employing sortase a in deep eutectic solvents
WO2017050866A1 (en) 2015-09-25 2017-03-30 F. Hoffmann-La Roche Ag Novel soluble sortase a
JP6895953B2 (ja) 2015-09-25 2021-06-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ソルターゼａを利用してチオエステルを作製するための方法
TWI811892B (zh) 2015-09-25 2023-08-11 美商建南德克公司 抗tigit抗體及使用方法
EP3353201B1 (en) 2015-09-25 2021-09-08 F. Hoffmann-La Roche AG Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
JP6657392B2 (ja) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
SI3356404T1 (sl) 2015-10-02 2021-11-30 F. Hoffmann-La Roche Ag Protitelesa proti PD1 in postopki uporabe
UA124925C2 (en) 2015-10-02 2021-12-15 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
US20190330335A1 (en) 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
IL295756A (en) 2015-10-29 2022-10-01 Hoffmann La Roche Antibodies against fc-variable region and methods of use
WO2017075432A2 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
CA3001362C (en) 2015-10-30 2020-10-13 Genentech, Inc. Anti-htra1 antibodies and methods of use thereof
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
PL3368579T3 (pl) 2015-10-30 2022-03-21 F. Hoffmann-La Roche Ag Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania
WO2017079768A1 (en) 2015-11-08 2017-05-11 Genentech, Inc. Methods of screening for multispecific antibodies
CA3005592C (en) 2015-12-18 2024-01-23 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
JP7046814B2 (ja) 2015-12-30 2022-04-04 ジェネンテック， インコーポレイテッド タンパク質製剤のためのトリプトファン誘導体の使用
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
CA3011739A1 (en) 2016-01-20 2017-07-27 Genentech, Inc. High dose treatments for alzheimer's disease
WO2017132279A1 (en) 2016-01-25 2017-08-03 Genentech, Inc. Methods for assaying t-cell dependent bispecific antibodies
CN109715821B (zh) 2016-01-29 2022-09-06 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
CA3019952A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
US11472877B2 (en) 2016-03-04 2022-10-18 Alector Llc Anti-TREM1 antibodies and methods of use thereof
WO2017156032A1 (en) 2016-03-07 2017-09-14 Charlestonpharma, Llc Anti-nucleolin antibodies
JP2019515876A (ja) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｎ−グリカンおよびそのアレイのモジュール合成のための方法
CA3016552A1 (en) 2016-03-15 2017-09-21 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
WO2017172990A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
WO2017167712A1 (en) 2016-03-30 2017-10-05 F. Hoffmann-La Roche Ag Improved sortase
WO2017180864A1 (en) 2016-04-14 2017-10-19 Genentech, Inc. Anti-rspo3 antibodies and methods of use
AU2017252128B2 (en) 2016-04-22 2024-06-06 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
SG11201809620UA (en) 2016-05-02 2018-11-29 Hoffmann La Roche The contorsbody - a single chain target binder
CN109071640B (zh) 2016-05-11 2022-10-18 豪夫迈·罗氏有限公司 经修饰抗生腱蛋白抗体及使用方法
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
IL262996B2 (en) 2016-06-06 2024-03-01 Hoffmann La Roche Fusion proteins for ophthalmology with increased grip in the eye
WO2017223405A1 (en) 2016-06-24 2017-12-28 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
EP3478717B1 (en) 2016-07-04 2022-01-05 F. Hoffmann-La Roche AG Novel antibody format
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
EP3490592A4 (en) 2016-07-27 2020-03-25 OBI Pharma, Inc. IMMUNOGENIC / THERAPEUTIC GLYCAN COMPOSITIONS AND USES THEREOF
CN117986372A (zh) 2016-07-29 2024-05-07 中外制药株式会社 显示增加的备选fviii辅因子功能活性的双特异性抗体
TWI786054B (zh) 2016-07-29 2022-12-11 台灣浩鼎生技股份有限公司 人類抗體、醫藥組合物、及其方法
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
EP3497129A1 (en) 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Therapeutic and diagnostic methods for cancer
JP7286536B2 (ja) 2016-08-15 2023-06-05 ジェネンテック， インコーポレイテッド 非イオン性サーファクタント及びポリペプチドを含む組成物中の非イオン性サーファクタントを定量するためのクロマトグラフィー法
EP3500594A4 (en) 2016-08-22 2020-03-11 Cho Pharma Inc. ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3515932B1 (en) 2016-09-19 2023-11-22 F. Hoffmann-La Roche AG Complement factor based affinity chromatography
RS64550B1 (sr) 2016-09-23 2023-09-29 Hoffmann La Roche Upotreba il-13 antagonista za lečenje atopičnog dermatitisa
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN110366558A (zh) 2016-10-28 2019-10-22 班扬生物标记公司 针对泛素c末端水解酶l1(uch-l1)和胶质纤维酸性蛋白(gfap)的抗体及相关方法
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
TWI767959B (zh) 2016-11-21 2022-06-21 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
CA3036983A1 (en) 2016-11-21 2018-05-24 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
MX2019006334A (es) 2016-12-07 2019-08-01 Genentech Inc Anticuerpos antitau y métodos de uso.
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
KR102293106B1 (ko) 2016-12-21 2021-08-24 에프. 호프만-라 로슈 아게 항체의 시험관 내 당조작 방법
CA3043158A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Re-use of enzymes in in vitro glycoengineering of antibodies
CA3044920C (en) 2016-12-21 2022-06-28 Roberto Falkenstein In vitro glycoengineering of antibodies
CN108239150A (zh) 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
WO2018136553A1 (en) 2017-01-18 2018-07-26 Genentech, Inc. Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
JP6995127B2 (ja) 2017-02-10 2022-02-04 ジェネンテック， インコーポレイテッド 抗トリプターゼ抗体、その組成物、及びその使用
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
NZ756132A (en) 2017-03-10 2022-02-25 Hoffmann La Roche Method for producing multispecific antibodies
PE20191758A1 (es) 2017-03-22 2019-12-12 Genentech Inc Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
CA3055985A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
CN108623686A (zh) 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
CN110494446A (zh) 2017-03-28 2019-11-22 基因泰克公司 治疗神经退行性疾病的方法
CA3053360A1 (en) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Anti-lag3 antibodies
TWI690538B (zh) 2017-04-05 2020-04-11 瑞士商赫孚孟拉羅股份公司 特異性結合至pd1至lag3的雙特異性抗體
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
EP3615572A1 (en) 2017-04-27 2020-03-04 Tesaro Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
US11203638B2 (en) 2017-05-05 2021-12-21 Allakos Inc. Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis
WO2018213097A1 (en) 2017-05-15 2018-11-22 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
EP3655430A1 (en) 2017-07-19 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
CN117700548A (zh) 2017-08-03 2024-03-15 艾利妥 抗cd33抗体及其使用方法
JP2020533948A (ja) 2017-08-03 2020-11-26 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
CN111295394B (zh) 2017-08-11 2024-06-11 豪夫迈·罗氏有限公司 抗cd8抗体及其用途
US11585014B2 (en) 2017-08-21 2023-02-21 Adagene Inc. Dynamic human antibody light chain libraries
CN111511762A (zh) 2017-08-21 2020-08-07 天演药业公司 抗cd137分子及其用途
IL272696B1 (en) 2017-08-21 2024-09-01 Adagene Inc Dynamic human heavy chain antibody libraries
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
EP3679068A2 (en) 2017-09-08 2020-07-15 Maverick Therapeutics, Inc. CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS
IL302613A (en) 2017-09-08 2023-07-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
JP6496095B1 (ja) 2017-09-29 2019-04-03 中外製薬株式会社 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤
AU2018347521A1 (en) 2017-10-12 2020-05-07 Immunowake Inc. VEGFR-antibody light chain fusion protein
EP3700540A4 (en) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS OF DEPRODUCTION FROM CD117 + CELLS
BR112020007736A2 (pt) 2017-10-30 2020-10-20 F. Hoffmann-La Roche Ag composição e método de tratamento
AU2018358904A1 (en) 2017-11-01 2020-04-16 F. Hoffmann-La Roche Ag TriFab-contorsbody
WO2019086394A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag The compbody - a multivalent target binder
EP3717517A1 (en) 2017-11-30 2020-10-07 H. Hoffnabb-La Roche Ag Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1
WO2019129136A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN109970857B (zh) 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CA3082280A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
CN111886246A (zh) 2017-12-29 2020-11-03 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
EP3731865A1 (en) 2017-12-29 2020-11-04 F. Hoffmann-La Roche AG Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
SG11202006348VA (en) 2018-01-05 2020-07-29 Ac Immune Sa Misfolded tdp-43 binding molecules
EP3740507A4 (en) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
WO2019143636A1 (en) 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
KR20200125590A (ko) 2018-01-26 2020-11-04 제넨테크, 인크. 조성물 및 사용 방법
TWI835772B (zh) 2018-01-26 2024-03-21 美商建南德克公司 Il-22fc融合蛋白及使用方法
WO2019152715A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
WO2019149269A1 (zh) 2018-02-01 2019-08-08 信达生物制药(苏州)有限公司 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
CA3091646A1 (en) 2018-02-14 2019-08-22 Abba Therapeutics Ag Anti-human pd-l2 antibodies
SG11202007694UA (en) 2018-02-21 2020-09-29 Genentech Inc DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
WO2019165434A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP3533459A1 (en) 2018-03-02 2019-09-04 Diaccurate Anti-pla2-gib antibodies and the uses thereof
EP3533460A1 (en) 2018-03-02 2019-09-04 Diaccurate Therapeutic anti-spla2-gib antibodies and the uses thereof
JP7497292B2 (ja) 2018-03-05 2024-06-10 エタブリスモン フランセ ドュ サン 遺伝子組換え単鎖免疫グロブリン
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
MX2020009296A (es) 2018-03-15 2020-11-13 Chugai Pharmaceutical Co Ltd Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.
TW202003567A (zh) 2018-03-30 2020-01-16 大陸商南京傳奇生物科技有限公司 針對lag-3之單一結構域抗體及其用途
WO2019192432A1 (zh) 2018-04-02 2019-10-10 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
FR3080621B1 (fr) 2018-04-26 2022-12-09 Univ Limoges Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde
US12084489B2 (en) 2018-05-02 2024-09-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection
CA3096703A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
CR20200566A (es) 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
WO2019235426A1 (ja) 2018-06-04 2019-12-12 中外製薬株式会社 細胞質内での半減期が変化した抗原結合分子
US20220125891A1 (en) 2018-06-06 2022-04-28 Osaka University Method for treating and/or preventing regnase-1-related disease
CN112512638A (zh) 2018-06-08 2021-03-16 艾利妥 抗siglec-7抗体及其使用方法
TWI819011B (zh) 2018-06-23 2023-10-21 美商建南德克公司 以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
AU2019293589A1 (en) 2018-06-29 2021-01-21 Alector Llc Anti-SIRP-beta1 antibodies and methods of use thereof
SI3618928T1 (sl) 2018-07-13 2023-04-28 Alector Llc Protitelesa proti sortilinu in postopki za uporabo le-teh
BR112021000772A2 (pt) 2018-07-17 2021-04-13 Humabs Biomed Sa Anticorpos contra espécies de campilobacter
KR20210032488A (ko) 2018-07-20 2021-03-24 서피스 온콜로지, 인크. 항-cd112r 조성물 및 방법
CN112739340A (zh) 2018-07-23 2021-04-30 美真达治疗公司 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途
SG11202100746WA (en) 2018-07-25 2021-03-30 Innovent Biologics Suzhou Co Ltd Anti-tigit antibody and use thereof
EA202190183A1 (ru) 2018-07-27 2021-05-18 Алектор Ллс Антитела к siglec-5 и способы их применения
SG11202101152QA (en) 2018-08-03 2021-03-30 Chugai Pharmaceutical Co Ltd Antigen-binding molecule containing two antigen-binding domains that are linked to each other
CA3106537A1 (en) 2018-08-08 2020-02-13 Genentech, Inc. Use of tryptophan derivatives and l-methionine for protein formulation
BR112021002037A2 (pt) 2018-08-10 2021-05-04 Chugai Seiyaku Kabushiki Kaisha molécula de ligação de antígeno anti-cd137 e uso da mesma
SG11202101552SA (en) 2018-08-31 2021-03-30 Alector Llc Anti-cd33 antibodies and methods of use thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019342133A1 (en) 2018-09-21 2021-04-22 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
CA3115887A1 (en) 2018-10-23 2020-04-30 Glycardial Diagnostics, S.L. Antibodies specific for glycosylated apoj and uses thereof
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
AU2019370485A1 (en) 2018-11-02 2021-05-13 Annexon, Inc. Compositions and methods for treating brain injury
CA3117051A1 (en) 2018-11-05 2020-05-14 Genentech, Inc. Methods of producing two chain proteins in prokaryotic host cells
TWI779253B (zh) 2018-11-27 2022-10-01 大陸商信達生物製藥（蘇州）有限公司 抗IL-23p19抗體及其用途
AU2018451747A1 (en) 2018-12-06 2021-06-17 F. Hoffmann-La Roche Ag Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
SI3898668T1 (sl) 2018-12-19 2024-02-29 Humabs Biomed Sa Protitelesa, ki nevtralizirajo virus hepatitisa B in njihove uporabe
JP2022514290A (ja) 2018-12-20 2022-02-10 ジェネンテック， インコーポレイテッド 改変抗体ｆｃおよび使用方法
US11130804B2 (en) 2018-12-21 2021-09-28 Hoffmann-La Roche Inc. Antibody that binds to VEGF and IL-1beta and methods of use
JP2022515543A (ja) 2018-12-30 2022-02-18 エフ．ホフマン－ラ ロシュ アーゲー 抗ウサギｃｄ１９抗体および使用方法
EP3914291A2 (en) 2019-01-22 2021-12-01 F. Hoffmann-La Roche AG Immunoglobulin a antibodies and methods of production and use
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CA3130695A1 (en) 2019-02-27 2020-09-03 Genentech, Inc. Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
CN114390938A (zh) 2019-03-05 2022-04-22 武田药品工业有限公司 受约束的条件性活化的结合蛋白
WO2020181145A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens
CN113474653A (zh) 2019-03-08 2021-10-01 豪夫迈·罗氏有限公司 用于检测和定量细胞外囊泡上的膜相关蛋白的方法
US20220153875A1 (en) 2019-03-19 2022-05-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
CN113711037A (zh) 2019-04-18 2021-11-26 基因泰克公司 抗体效力测定
KR20220002967A (ko) 2019-04-19 2022-01-07 제넨테크, 인크. 항 mertk 항체 및 이의 사용 방법
KR20220003572A (ko) 2019-04-24 2022-01-10 하이델베르크 파마 리서치 게엠베하 아마톡신 항체-약물 결합체 및 이의 용도
MX2021012872A (es) 2019-04-25 2021-11-17 Hoffmann La Roche Polipeptidos multiespecificos terapeuticos activados mediante intercambio de cadenas polipeptidicas.
CA3132275A1 (en) 2019-04-25 2020-10-29 Ulrich Brinkmann Generation of antibody-derived polypeptides by polypeptide chain exchange
CA3133898A1 (en) 2019-04-25 2020-10-29 Ulrich Brinkmann Activatable therapeutic multispecific polypeptides with extended half-life
AU2020275415A1 (en) 2019-05-14 2021-11-25 Genentech, Inc. Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
WO2020234473A1 (en) 2019-05-23 2020-11-26 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
CN114423450A (zh) 2019-06-11 2022-04-29 艾利妥有限责任公司 用于疗法中的抗分拣蛋白抗体
MX2022000111A (es) 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd Moleculas de union a claudina-6 y usos de las mismas.
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
CN114341181A (zh) 2019-07-31 2022-04-12 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
CA3148740A1 (en) 2019-08-06 2021-02-11 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
EP3786180A1 (en) 2019-08-27 2021-03-03 Diaccurate Antibodies and the uses thereof
US20220380441A1 (en) 2019-08-29 2022-12-01 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
CA3148990A1 (en) 2019-08-29 2021-03-04 Vir Biotechnology, Inc. Compositions and methods for treatment of influenza a infection
MX2022002738A (es) 2019-09-04 2022-06-27 Genentech Inc Agentes de union a cd8 y uso de los mismos.
TW202118512A (zh) 2019-09-12 2021-05-16 美商建南德克公司 治療狼瘡性腎炎之組成物及方法
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
AU2020349509A1 (en) 2019-09-18 2022-03-31 Genentech, Inc. Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
CA3150726A1 (en) 2019-09-20 2021-03-25 Jing Guo Anti-alpha-synuclein antibodies and methods of use thereof
MX2022003610A (es) 2019-09-27 2022-04-20 Genentech Inc Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
EP4034160A1 (en) 2019-09-27 2022-08-03 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
WO2021057978A1 (zh) 2019-09-27 2021-04-01 南京金斯瑞生物科技有限公司 抗vhh域抗体及其用途
MX2022004443A (es) 2019-10-18 2022-05-02 Genentech Inc Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
CA3158893A1 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
WO2021092171A1 (en) 2019-11-06 2021-05-14 Genentech, Inc. Diagnostic and therapeutic methods for treatment of hematologic cancers
CN117106069B (zh) 2019-11-11 2024-06-11 珠海泰诺麦博制药股份有限公司 抗水痘-带状疱疹病毒的抗体
EP4057980A1 (en) 2019-11-15 2022-09-21 F. Hoffmann-La Roche AG Prevention of visible particle formation in aqueous protein solutions
MX2022005850A (es) 2019-11-15 2022-08-15 Univ Tennessee Res Found Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo.
KR20220110537A (ko) 2019-12-05 2022-08-08 알렉터 엘엘씨 항-trem2 항체 사용 방법
US12076400B2 (en) 2019-12-06 2024-09-03 Zymeworks Bc Inc. Methods of using a bispecific antigen-binding construct targeting HER2 in combination with CDK4/6 inhibitors for the treatment of breast cancer
JP2023506014A (ja) 2019-12-12 2023-02-14 アレクトル エルエルシー 抗ｃｄ３３抗体の使用方法
TW202128767A (zh) 2019-12-13 2021-08-01 美商建南德克公司 抗ly6g6d抗體及其使用方法
KR20220127252A (ko) 2019-12-13 2022-09-19 알렉터 엘엘씨 항-mertk 항체 및 이의 사용 방법
CA3164818A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
PE20221186A1 (es) 2019-12-23 2022-08-05 Genentech Inc Anticuerpos especificos de apolipoproteina l1 y metodos de uso
IL294226A (en) 2019-12-27 2022-08-01 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibodies and their use
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
JP2023511074A (ja) 2020-01-15 2023-03-16 トゥティーノ・バイオサイエンシーズ・インコーポレイテッド 切断可能リンカーを含むサイトカインプロドラッグ
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
US20230078601A1 (en) 2020-01-31 2023-03-16 The Cleveland Clinic Foundation Anti-mullerian hormone receptor 2 antibodies and methods of use
BR112022015374A2 (pt) 2020-02-03 2022-10-11 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
KR20220139357A (ko) 2020-02-10 2022-10-14 상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 Cldn18.2 항체 및 그의 사용
KR20220140786A (ko) 2020-02-10 2022-10-18 상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 클라우딘18.2 항체 및 그것의 사용
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
EP4110814A1 (en) 2020-02-24 2023-01-04 Alector LLC Methods of use of anti-trem2 antibodies
AU2021227687B2 (en) 2020-02-26 2023-02-23 Vir Biotechnology, Inc. Antibodies against SARS-CoV-2 and methods of using the same
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Antibodies against interleukin-33 and uses thereof
KR20220156575A (ko) 2020-03-19 2022-11-25 제넨테크, 인크. 동종형 선택적 항-tgf-베타 항체 및 이용 방법
JP2023519213A (ja) 2020-03-24 2023-05-10 ジェネンテック， インコーポレイテッド Ｔｉｅ２結合剤および使用方法
WO2021198034A1 (en) 2020-03-30 2021-10-07 F. Hoffmann-La Roche Ag Antibody that binds to vegf and pdgf-b and methods of use
CN116075525A (zh) 2020-03-31 2023-05-05 艾莱克特有限责任公司 抗mertk抗体及其使用方法
KR20220161375A (ko) 2020-03-31 2022-12-06 추가이 세이야쿠 가부시키가이샤 다중 특이성 항원 결합 분자를 제조하기 위한 방법
US20230107644A1 (en) 2020-04-01 2023-04-06 University Of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
WO2021201202A1 (ja) 2020-04-02 2021-10-07 中外製薬株式会社 多重特異性抗原結合分子を含む組成物における不純物分子の分析方法
KR20230005848A (ko) 2020-04-03 2023-01-10 알렉터 엘엘씨 항-trem2 항체의 사용 방법
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
EP4135846A1 (en) 2020-04-14 2023-02-22 VIR Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
CN117186219B (zh) 2020-04-17 2024-07-12 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CR20220531A (es) 2020-04-24 2022-11-28 Hoffmann La Roche Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
CN115916822A (zh) 2020-04-24 2023-04-04 基因泰克公司 使用抗CD79b免疫缀合物的方法
MX2021015024A (es) 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
CA3174692A1 (en) 2020-04-30 2021-11-04 Genentech, Inc. Kras specific antibodies and uses thereof
KR20230087414A (ko) 2020-05-03 2023-06-16 레베나 (쑤저우) 바이오파마 컴퍼니 리미티드 항-Trop-2 항체를 포함하는 항체-약물 접합체 (ADCS), 상기 ADCS를 포함하는 조성물, 및 이의 제조 및 사용 방법
CA3177169A1 (en) 2020-05-08 2021-11-11 Vir Biotechnology, Inc. Antibodies against sars-cov-2
CN115605184A (zh) 2020-05-15 2023-01-13 豪夫迈·罗氏有限公司（Ch） 防止胃肠外蛋白质溶液中的可见颗粒形成
EP4153130A1 (en) 2020-05-19 2023-03-29 F. Hoffmann-La Roche AG The use of chelators for the prevention of visible particle formation in parenteral protein solutions
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
MX2022015206A (es) 2020-06-08 2023-01-05 Hoffmann La Roche Anticuerpos anti-hbv y metodos de uso.
JP2023530274A (ja) 2020-06-12 2023-07-14 ヴィア・バイオテクノロジー・インコーポレイテッド ＳＡＲＳ－ＣｏＶ－２感染の抗体療法
CA3181820A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
TW202200616A (zh) 2020-06-18 2022-01-01 美商建南德克公司 使用抗tigit抗體及pd-1軸結合拮抗劑之治療
TW202208422A (zh) 2020-06-24 2022-03-01 美商維爾生物科技股份有限公司 經工程化之b型肝炎病毒中和抗體及其用途
CN116133689A (zh) 2020-07-07 2023-05-16 豪夫迈·罗氏有限公司 作为治疗性蛋白质制剂的稳定剂的替代表面活性剂
BR112023000204A2 (pt) 2020-07-10 2023-01-31 Hoffmann La Roche Conjunto de anticorpos, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira, métodos de pré-direcionamento de radioimunoterapia e direcionamento de um radioisótopo, ligante peptídico, proteína de múltiplos domínios e usos
EP4182688A1 (en) 2020-07-14 2023-05-24 F. Hoffmann-La Roche AG Assays for fixed dose combinations
EP3939999A1 (en) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
JP2023534458A (ja) 2020-07-17 2023-08-09 ジェネンテック， インコーポレイテッド 抗Ｎｏｔｃｈ２抗体及び使用方法
MX2023000888A (es) 2020-07-21 2023-02-22 Genentech Inc Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos.
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
KR20230041071A (ko) 2020-07-31 2023-03-23 제넨테크, 인크. 항-인테그린 베타7 항체 제제 및 장치
BR112023002123A2 (pt) 2020-08-07 2023-03-07 Genentech Inc Proteína de fusão fc, ácidos nucleicos isolados, método de produção da proteína de fusão fc, formulação farmacêutica, métodos para expandir o número de células dendríticas (dcs) em um indivíduo e para tratar um câncer, proteína fc sem efetora e anticorpo
JP2023537761A (ja) 2020-08-14 2023-09-05 エイシー イミューン ソシエテ アノニム ヒト化抗ｔｄｐ－４３結合分子およびその使用
WO2022043517A2 (en) 2020-08-27 2022-03-03 Cureab Gmbh Anti-golph2 antibodies for macrophage and dendritic cell differentiation
PE20230986A1 (es) 2020-09-04 2023-06-21 Hoffmann La Roche Anticuerpo que se une a vegf-a y ang2, y metodos de uso
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
WO2022066965A2 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting sox2 antigens
EP4217385A2 (en) 2020-09-28 2023-08-02 VIR Biotechnology, Inc. Antibodies against sars-cov-2
KR20230082632A (ko) 2020-10-05 2023-06-08 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
JP2023545821A (ja) 2020-10-16 2023-10-31 ジェネンテック， インコーポレイテッド 抗ｉＣａｓｐａｓｅ切断基質抗体および使用方法
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
CA3192306A1 (en) 2020-10-20 2022-04-28 Burkhard Ludewig Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
TW202227481A (zh) 2020-11-04 2022-07-16 美國洛克菲勒大學 中和抗sars-cov-2抗體
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
KR20230100732A (ko) 2020-11-04 2023-07-05 제넨테크, 인크. 항-cd20/항-cd3 이중특이성 항체의 피하 투여
KR20230095113A (ko) 2020-11-04 2023-06-28 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
JP2023551666A (ja) 2020-11-23 2023-12-12 ヴィア・バイオテクノロジー・インコーポレイテッド Ａ型インフルエンザウイルスに対する抗体
EP4247845A1 (en) 2020-11-23 2023-09-27 VIR Biotechnology, Inc. Anti-influenza antibodies and combinations thereof
EP4247495A1 (en) 2020-11-23 2023-09-27 VIR Biotechnology, Inc. Broadly neutralizing antibodies against influenza neuraminidase
EP4251279A1 (en) 2020-11-25 2023-10-04 VIR Biotechnology, Inc. Antibodies that bind to multiple betacoronaviruses
US20240101681A1 (en) 2020-12-02 2024-03-28 Alector Llc Methods of use of anti-sortilin antibodies
JP2023551983A (ja) 2020-12-07 2023-12-13 ユーシービー バイオファルマ エスアールエル インターロイキン－２２に対する抗体
IL303295A (en) 2020-12-07 2023-07-01 UCB Biopharma SRL Multispecific antibodies and antibody combinations
WO2022125517A1 (en) 2020-12-08 2022-06-16 Vir Biotechnology, Inc. Antibodies and methods for treatment of influenza a infection
AU2021399841A1 (en) 2020-12-17 2023-07-06 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
CN117098548A (zh) 2020-12-23 2023-11-21 信达生物制药(苏州)有限公司 抗b7-h3抗体及其用途
KR20230117406A (ko) 2021-01-06 2023-08-08 에프. 호프만-라 로슈 아게 Pd1-lag3 이중특이성 항체와 cd20 t 세포 이중특이성항체를 이용한 조합 요법
WO2022152656A1 (en) 2021-01-12 2022-07-21 F. Hoffmann-La Roche Ag Split antibodies which bind to cancer cells and target radionuclides to said cells
US12060411B2 (en) 2021-01-15 2024-08-13 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
JP2024504372A (ja) 2021-01-22 2024-01-31 エルピス・バイオファーマシューティカルズ 抗ｐｄ－ｌ１モノクローナル抗体及びインターロイキン１５（ｉｌ－１５）、インターロイキン１５受容体１５アルファまたはインターロイキン２との融合タンパク質
WO2022159842A1 (en) 2021-01-25 2022-07-28 Vir Biotechnology, Inc. Antibody combination therapies for sars-cov-2 infection
JP2024504167A (ja) 2021-01-26 2024-01-30 ヴィア・バイオテクノロジー・インコーポレイテッド Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
WO2022162587A1 (en) 2021-01-27 2022-08-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
KR20230147099A (ko) 2021-01-28 2023-10-20 백신벤트 게엠베하 B 세포 매개 면역 반응을 조절하기 위한 방법 및 수단(method and means for modulating b-cell mediated immune responses)
WO2022162203A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
CN117120084A (zh) 2021-01-28 2023-11-24 维肯芬特有限责任公司 用于调节b细胞介导的免疫应答的方法和手段
EP4288458A1 (en) 2021-02-03 2023-12-13 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
AU2022217058A1 (en) 2021-02-04 2023-09-21 Genuv Inc. Anti-pd-1 antibody and use thereof
EP4289865A1 (en) 2021-02-04 2023-12-13 Innovent Biologics (Suzhou) Co., Ltd. Anti-tnfr2 antibody and use thereof
WO2022173745A1 (en) 2021-02-09 2022-08-18 Humabs Biomed Sa Antibodies against respiratory syncytial virus, human metapneumovirus and pneumonia virus of mice and methods of using the same
EP4301418A1 (en) 2021-03-03 2024-01-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates comprising an anti-bcma antibody
CA3211581A1 (en) 2021-03-10 2022-09-15 Ellen WU Immunomodulatory molecules and uses thereof
EP4304732A1 (en) 2021-03-12 2024-01-17 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
MX2023010812A (es) 2021-03-15 2023-09-27 Genentech Inc Composiciones y metodos para tratar la nefritis lupica.
CA3213295A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
JP2024512002A (ja) 2021-03-18 2024-03-18 アレクトル エルエルシー 抗ｔｍｅｍ１０６ｂ抗体、及び、その使用方法
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2022204274A1 (en) 2021-03-23 2022-09-29 Alector Llc Anti-tmem106b antibodies for treating and preventing coronavirus infections
WO2022204724A1 (en) 2021-03-25 2022-09-29 Dynamicure Biotechnology Llc Anti-igfbp7 constructs and uses thereof
EP4067376A1 (en) 2021-03-30 2022-10-05 Diaccurate Anti-pla2g1b monoclonal antibodies and uses thereof
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
EP4329887A1 (en) 2021-04-28 2024-03-06 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
JP2024516305A (ja) 2021-05-03 2024-04-12 ユーシービー バイオファルマ エスアールエル 抗体
EP4334343A2 (en) 2021-05-06 2024-03-13 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
IL308351A (en) 2021-05-12 2024-01-01 Genentech Inc Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
WO2022241082A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Agonists of trem2
EP4347642A2 (en) 2021-05-24 2024-04-10 VIR Biotechnology, Inc. Engineered polypeptides
US20230036592A1 (en) 2021-06-03 2023-02-02 Surface Oncology, Inc. Methods of treating cancer with an anti-cd39 antibody and pembrolizumab
CN117480184A (zh) 2021-06-04 2024-01-30 中外制药株式会社 抗ddr2抗体及其用途
EP4355786A1 (en) 2021-06-16 2024-04-24 Alector LLC Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
JP2024527493A (ja) 2021-06-16 2024-07-25 アレクトル エルエルシー 一価の抗ＭｅｒＴＫ抗体及びその使用方法
CN117500826A (zh) 2021-06-17 2024-02-02 基因泰克公司 抗泛素化抗体及其使用方法
WO2022263638A1 (en) 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
AU2022295067A1 (en) 2021-06-18 2023-12-21 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
CA3220353A1 (en) 2021-06-25 2022-12-29 Chugai Seiyaku Kabushiki Kaisha Use of anti-ctla-4 antibody
CA3221833A1 (en) 2021-06-25 2022-12-29 Chugai Seiyaku Kabushiki Kaisha Anti-ctla-4 antibody
WO2023288182A1 (en) 2021-07-12 2023-01-19 Genentech, Inc. Structures for reducing antibody-lipase binding
JP2024527606A (ja) 2021-07-14 2024-07-25 ジェネンテック， インコーポレイテッド 抗ｃ－ｃモチーフケモカイン受容体８（ｃｃｒ８）抗体及び使用方法
WO2023004368A1 (en) 2021-07-21 2023-01-26 Trutino Biosciences Inc. Linker polypeptides
WO2023004386A1 (en) 2021-07-22 2023-01-26 Genentech, Inc. Brain targeting compositions and methods of use thereof
EP4373859A1 (en) 2021-07-22 2024-05-29 F. Hoffmann-La Roche AG Heterodimeric fc domain antibodies
EP4380980A1 (en) 2021-08-03 2024-06-12 F. Hoffmann-La Roche AG Bispecific antibodies and methods of use
KR20240045314A (ko) 2021-08-18 2024-04-05 필립모리스 프로덕츠 에스.에이. 항체 및 이의 항원 결합 단편
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
JP2024534067A (ja) 2021-08-19 2024-09-18 エフ． ホフマン－ラ ロシュ アーゲー 多価抗バリアントｆｃ領域抗体および使用方法
AU2022332303A1 (en) 2021-08-27 2024-02-01 Genentech, Inc. Methods of treating tau pathologies
WO2023028603A2 (en) 2021-08-27 2023-03-02 Humabs Biomed Sa Engineered compositions
EP4396223A1 (en) 2021-08-30 2024-07-10 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
WO2023034866A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. Antibody therapies for sars-cov-2 infection in pediatric subjects
WO2023034871A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. High concentration antibody therapies for sars-cov-2 infection
EP4399228A1 (en) 2021-09-07 2024-07-17 Etablissement Français du Sang Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering
WO2023039442A1 (en) 2021-09-08 2023-03-16 Vir Biotechnology, Inc. Broadly neutralizing antibody combination therapies for sars-cov-2 infection
JPWO2023053282A1 (no) 2021-09-29 2023-04-06
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
AR127269A1 (es) 2021-10-08 2024-01-03 Chugai Pharmaceutical Co Ltd Formulación de anticuerpo anti-hla-dq2.5
EP4419558A1 (en) 2021-10-19 2024-08-28 Alector LLC Anti-cd300lb antibodies and methods of use thereof
WO2023081818A1 (en) 2021-11-05 2023-05-11 American Diagnostics & Therapy, Llc (Adxrx) Monoclonal antibodies against carcinoembryonic antigens, and their uses
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
EP4433506A1 (en) 2021-11-16 2024-09-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
MX2024005876A (es) 2021-11-16 2024-05-29 Ac Immune Sa Moleculas novedosas para terapias y diagnostico.
EP4448578A1 (en) 2021-12-17 2024-10-23 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
AU2022411573A1 (en) 2021-12-17 2024-06-27 Shanghai Henlius Biologics Co., Ltd. Anti-ox40 antibodies and methods of use
TW202340251A (zh) 2022-01-19 2023-10-16 美商建南德克公司 抗ｎｏｔｃｈ２抗體及結合物及其使用方法
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
TW202342519A (zh) 2022-02-16 2023-11-01 瑞士商Ａｃ 免疫有限公司 人源化抗ｔｄｐ－４３結合分子及其用途
AU2023225020A1 (en) 2022-02-23 2024-09-12 Alector Llc Methods of use of anti-trem2 antibodies
EP4238988A1 (en) 2022-03-01 2023-09-06 Consejo Superior De Investigaciones Científicas Antibodies against sars-cov-2 and uses thereof
WO2023180353A1 (en) 2022-03-23 2023-09-28 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
WO2023179740A1 (en) 2022-03-25 2023-09-28 Shanghai Henlius Biotech , Inc. Anti-msln antibodies and methods of use
AU2022450448A1 (en) 2022-04-01 2024-10-10 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023194565A1 (en) 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules
WO2023201256A1 (en) 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
TW202404637A (zh) 2022-04-13 2024-02-01 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
AR129062A1 (es) 2022-04-13 2024-07-10 Genentech Inc Composiciones farmacéuticas de proteínas terapéuticas y métodos de uso
WO2023201291A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
AU2023258146A1 (en) 2022-04-20 2024-09-05 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
WO2023215737A1 (en) 2022-05-03 2023-11-09 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
AR129268A1 (es) 2022-05-11 2024-08-07 Hoffmann La Roche Anticuerpo que se une a vegf-a e il6 y métodos de uso
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023230448A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza
WO2023230439A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof
TW202411247A (zh) 2022-05-23 2024-03-16 瑞士商休曼生物醫藥股份公司 針對流感神經胺酸酶的廣泛中和抗體
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2023237706A2 (en) 2022-06-08 2023-12-14 Institute For Research In Biomedicine (Irb) Cross-specific antibodies, uses and methods for discovery thereof
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
WO2023245105A1 (en) 2022-06-17 2023-12-21 Genentech, Inc. Use of kosmotropes to enhance yield of an affinity chromatography purification step
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
TW202417042A (zh) 2022-07-13 2024-05-01 美商建南德克公司 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020564A1 (en) 2022-07-22 2024-01-25 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
TW202423963A (zh) 2022-07-27 2024-06-16 瑞士商休曼斯生物醫藥公司 針對ｒｓｖ及ｍｐｖ副黏液病毒之廣效中和抗體
TW202415679A (zh) 2022-07-29 2024-04-16 美商阿列克特有限責任公司 抗ｇｐｎｍｂ抗體及其使用方法
WO2024052922A1 (en) 2022-09-11 2024-03-14 Yeda Research And Development Co. Ltd. Anti-klk4 antibodies and uses thereof
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
TW202421664A (zh) 2022-10-07 2024-06-01 美商建南德克公司 用抗ｃ—ｃ模體趨化因子受體８（ｃｃｒ８）抗體治療癌症之方法
WO2024079074A1 (en) 2022-10-10 2024-04-18 Universite D'aix Marseille ANTI-sCD146 ANTIBODIES AND USES THEREOF
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
TW202426505A (zh) 2022-10-25 2024-07-01 美商建南德克公司 癌症之治療及診斷方法
WO2024102734A1 (en) 2022-11-08 2024-05-16 Genentech, Inc. Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024100200A1 (en) 2022-11-09 2024-05-16 Cis Pharma Ag Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
WO2024104988A1 (en) 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Recombinant binding proteins with activatable effector domain
WO2024107749A1 (en) 2022-11-16 2024-05-23 Attralus, Inc. Fusion proteins that bind amyloid and the transferrin receptor and uses thereof
WO2024112818A1 (en) 2022-11-22 2024-05-30 Humabs Biomed Sa Engineered anti-sars-cov-2 antibodies and uses thereof
WO2024118998A2 (en) 2022-12-01 2024-06-06 Vir Biotechnology, Inc. Engineered anti-sars-cov-2 antibodies and methods of using the same
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)
WO2024148232A2 (en) 2023-01-06 2024-07-11 Alector Llc Anti-il18 binding protein antibodies and methods of use thereof
WO2024155807A1 (en) 2023-01-18 2024-07-25 Genentech, Inc. Multispecific antibodies and uses thereof
WO2024182781A1 (en) 2023-03-02 2024-09-06 Vir Biotechnology, Inc. Coronavirus compositions and uses thereof
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
WO2024191785A1 (en) 2023-03-10 2024-09-19 Genentech, Inc. Fusions with proteases and uses thereof
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
US20240327522A1 (en) 2023-03-31 2024-10-03 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963495A (en) * 1984-10-05 1990-10-16 Genentech, Inc. Secretion of heterologous proteins
US5232840A (en) * 1986-03-27 1993-08-03 Monsanto Company Enhanced protein production in bacteria by employing a novel ribosome binding site

Also Published As

Publication number Publication date
RU2208639C2 (ru) 2003-07-20
DE69636996D1 (de) 2007-05-10
EP0815246B1 (en) 2007-03-28
ZA961688B (en) 1997-09-01
MX9706607A (es) 1997-11-29
DE69636996T2 (de) 2007-12-06
FI973559A (fi) 1997-10-29
NO324920B1 (no) 2008-01-07
BR9607464B1 (pt) 2009-01-13
CA2213813A1 (en) 1996-09-06
NO973985D0 (no) 1997-08-29
NZ303619A (en) 2000-02-28
US5840523A (en) 1998-11-24
DK0815246T3 (da) 2007-08-06
FI973559A0 (fi) 1997-08-29
AU701476B2 (en) 1999-01-28
JP3375970B2 (ja) 2003-02-10
AU4998496A (en) 1996-09-18
ES2285711T3 (es) 2007-11-16
BR9607464A (pt) 1997-12-23
IL117314A0 (en) 1996-06-18
EP0815246A1 (en) 1998-01-07
CN1180379A (zh) 1998-04-29
NO973985L (no) 1997-10-29
ATE358181T1 (de) 2007-04-15
CN1154736C (zh) 2004-06-23
JPH10507368A (ja) 1998-07-21
WO1996027016A1 (en) 1996-09-06
CA2213813C (en) 2008-05-27

Similar Documents

Publication Publication Date Title
FI120357B (fi) Menetelmiä ja koostumuksia heterologisten polypeptidien erittämiseksi
EP0012494B1 (en) A dna transfer vector, a microorganism modified by said vector and the synthesis of a eucaryotic protein by the modified microorganism
EP0288451B1 (en) Secretion of insulin-like growth factor 1 in E. coli
US5747662A (en) Methods and compositions for secretion of heterologous polypeptides
NZ283214A (en) Rh signal peptide used for improving secretion of ngf polypeptides and preparing met-less ngf polypeptides
US5489517A (en) Secretion of insulin-like growth factor-I in E. coli
EP0111389A2 (en) Substantially pure porcine growth hormone, DNA sequences therefor, and expression vehicles and transfected microorganisms for the production of porcine growth hormone
KR100737189B1 (ko) 배양 배지에서 대장균에 의한 분비를 통한 Ｌｅｕ-히루딘의 제조를 위한 시그날 서열
CA2221587C (en) Promoters for gene expression
US6242177B1 (en) Methods and compositions for secretion of heterologous polypeptides
KR100963302B1 (ko) 대장균 유래 ｐｔｓＬ 프로모터를 함유하는 재조합벡터 및이를 이용한 외래 단백질의 제조방법
FI97549C (fi) Menetelmä vierasproteiinien valmistamiseksi Streptomycessoluissa
Fujimoto et al. Expression and secretion of human epidermal growth factor by Escherichia coli using enterotoxin signal sequences
WO1986005805A1 (en) A dna sequence
MXPA97006607A (en) Methods and compositions for secretion of heterolo polypeptides
JPH07143885A (ja) ポリペプチドをコード化するｄｎａ配列
EP0547873B1 (en) A novel translational activating sequence
WO1995010620A1 (en) A plasmid vector useful for the expression of a foreign dna sequence

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120357

Country of ref document: FI

MA Patent expired